Abstract
Purpose of Review
The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine.
Recent Findings
Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options.
Summary
A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97. https://doi.org/10.1016/S1474-4422(17)30299-5.
Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. https://doi.org/10.1016/S0140-6736(15)60692-4.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. https://doi.org/10.1212/WNL.0b013e3182535d20.
Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. https://doi.org/10.1111/head.13081.
Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(27):887–98. https://doi.org/10.1177/0333102416653233.
Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–98. https://doi.org/10.1177/0333102416653233.
Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18(1):96. https://doi.org/10.1186/s10194-017-0807-1.
Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg. 2017;154:74–8. https://doi.org/10.1016/j.clineuro.2017.01.009.
•• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;1:333102418759786. https://doi.org/10.1177/0333102418759786. Recently published phase III trial examining CGRP receptor antibody erenumab.
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–93. https://doi.org/10.1001/jamaneurol.2017.3859. Recently published phase IIb trial examining CGRP antibody galcanezumab.
•• Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. https://doi.org/10.1056/NEJMoa1709038. Recently published phase III trial examining CGRP antibody fremanezumab.
Somerville BW. Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology. 1976;26:41–5.
Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97. https://doi.org/10.1016/j.pharmthera.2018.01.005.
Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–26. https://doi.org/10.2147/JPR.S132833.
Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). 2017. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT02605174?term=lasmiditan&rank=1. https://investor.lilly.com/releasedetail.cfm?ReleaseID=1036101
An open-label, long-term, safety study of lasmiditan for the acute treatment of migraine (GLADIATOR). 2017. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02565186?term=GLADIATOR&rank=3.
Sundrum T, Walker CS. PACAP receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol. 2017; https://doi.org/10.1111/bph.14053.
Edvinsson L, Tatji J, Szalardy L, Vecsei L. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21. https://doi.org/10.1186/s10194-018-0852-4.
Waschek JA, Baca SM, Akerman S. PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain. 2018;19(1):23. https://doi.org/10.1186/s10194-018-0850-6.
Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7(308):308ra157. https://doi.org/10.1126/scitranslmed.aaa7557.
Puledda F, Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache. 2017;57(4):685–91. https://doi.org/10.1111/head.13069.
Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80. https://doi.org/10.1016/S1474-4422(10)70054-5.
Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535. https://doi.org/10.1186/s10194-015-0535-3.
Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018;1: 333102418762525:1038–48. https://doi.org/10.1177/0333102418762525.
Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly device for migraine prevention: a review of the available data. Pain Ther. 2015;4:135–47. https://doi.org/10.1007/s40122-015-0039-5.
Magis D, D’Ostilio K, Thibaut A, de Pasqua V, Gerard P, Hustinx R, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2017;37(9):881–91. https://doi.org/10.1177/0333102416656118.
Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704. https://doi.org/10.1212/WNL.0b013e3182825055.
Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(95) https://doi.org/10.1186/1129-2377-14-95.
Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88:1250–5. https://doi.org/10.1212/WNL.0000000000003760.
Oshinsky ML, Murphy AL, Hekierski H Jr, Cooper M, Simon BJ. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain. 2014;155(5):1037–42. https://doi.org/10.1016/j.pain.2014.02.009.
Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016;157(4):797–805. https://doi.org/10.1097/j.pain.0000000000000437.
Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–93. https://doi.org/10.1177/0333102414524494.
Tassorelli C, Grazzi L, De Tommaso M, et al. The PRESTO Trial. Neurology 2018; 90 (15 Supplement).
Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D, et al. Migraine prevention with percutaneous mastoid electrical stimulator: a randomized double-blind controlled trial. Cephalalgia. 2017;37(13):1248–56. https://doi.org/10.1177/0333102416678623.
Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, et al. Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial. Headache. 2017;57:1065–87. https://doi.org/10.1111/head.13120.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Kate W. Grimsrud declares no conflict of interest. Rashmi B. Halker Singh has received consulting fees from Amgen and Allergan.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Episodic Migraine
Rights and permissions
About this article
Cite this article
Grimsrud, K.W., Halker Singh, R.B. Emerging Treatments in Episodic Migraine. Curr Pain Headache Rep 22, 61 (2018). https://doi.org/10.1007/s11916-018-0716-2
Published:
DOI: https://doi.org/10.1007/s11916-018-0716-2